Prasugrel—The Default P2Y12 Inhibitor After PCI for ACS?

Дата публикации: 01-08-2026 00:00:00

Dual antiplatelet therapy remains a mainstay in patients undergoing percutaneous coronary intervention (PCI) after an acute coronary syndrome (ACS), yet selecting the most appropriate P2Y12 inhibitor remains quite challenging. JAMA Cardiology features a landmark network meta-analysis by Maqsood and colleagues using aggregate data from randomized clinical trials comparing clopidogrel, prasugrel, and ticagrelor in patients undergoing PCI, mostly with ACS. This timely and well-conducted exercise in evidence synthesis, despite the limitations inherent to any similar scholarly effort, provides important insights for clinical practice.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk	0	7.22	01-08-2026
2	The impact of smoking status on clopidogrel responsiveness in patients with coronary artery disease who undergo percutaneous coronary intervention. [version 3; peer review: 1 approved, 1 not approved]	0	5.86	27-07-2026
3	Interpreting the APERITIF Randomized Clinical Trial	0	13.07	01-08-2026
4	Interpreting the APERITIF Randomized Clinical Trial—Reply	0	10.38	01-08-2026
5	JAMA Cardiology	0	7.83	01-08-2026
6	Coronary Artery Calcium Progression—A Useful Outcome in Clinical Trials?	0	9.46	01-08-2026
7	Cardiotoxicity of Immune Checkpoint Inhibitors	0	8	01-10-2024
8	Common heart drug taken by millions found useless — and possibly dangerous	0	7.99	25-05-2026
9	Error in Correction Notice Reference	0	7.69	01-08-2026
10	Error in Figure	0	14.84	01-08-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7.98. Источник: archderm.jamanetwork.com.